Sigma Genetics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sigma Genetics is a private, pre-revenue platform technology company pioneering a magnetic field-based approach to intracellular delivery. Its core innovation, the Magnetoporator™, aims to overcome key limitations of existing transfection and electroporation methods by using magnetic induction to create nanosecond pulsed electric fields, potentially offering greater efficiency, scalability, and adjustability. The platform is positioned to serve the high-growth markets of cell and gene therapy development, drug discovery, and biomanufacturing. As an early-stage company, its success hinges on robust validation, strategic partnerships, and securing further funding to advance its technology toward commercial adoption.

Drug Delivery

Technology Platform

Magnetoporator™: A platform using magnetic fields to induce nanosecond pulsed electric fields (nsPEF) for intracellular delivery of diverse payloads into various cell types.

Opportunities

The rapid expansion of the cell and gene therapy market creates a massive, urgent need for improved non-viral delivery technologies that are efficient, scalable, and gentle on cells.

Sigma Genetics' platform, if validated, could become a critical enabling tool for therapy developers and contract manufacturers.

The adjustable nature of the technology also allows it to target adjacent markets in drug discovery and bioproduction.

Risk Factors

The company faces significant technical risk in proving its platform's superiority over established and emerging competitors.

As a pre-revenue, private startup, it is also highly dependent on securing venture funding to continue operations and faces substantial commercialization challenges in translating a prototype into a robust, user-friendly, and regulated instrument.

Competitive Landscape

Sigma Genetics competes in the crowded intracellular delivery market against major players like Lonza (Nucleofector®) and MaxCyte (Flow Electroporation®), as well as numerous startups exploring alternative physical methods (e.g., acoustic, microfluidic) and advanced chemical vectors. Differentiation hinges on conclusively demonstrating that its magnetic field-induced nsPEF approach offers unique advantages in efficiency, cell health, and scalability for the most therapeutically relevant cell types.

More companies in Drug Delivery & Formulation →More companies in United States →